TY - JOUR
T1 - Shortened time to neuromuscular recovery with lower doses of rocuronium in elderly patients
AU - Wadland, Sarah Sofie
AU - Rasmussen, Lars Simon
AU - Vested, Matias
N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.
PY - 2024/5/13
Y1 - 2024/5/13
N2 - INTRODUCTION: The effect of neuromuscular blocking agents may be reversed by administration of neostigmine, when two twitches are present using train-of-four (TOF) stimulation. However, in elderly patients, limited data are available about when to administer neostigmine. We hypothesised that time to two twitches after TOF (TOF-2) was shorter after rocuronium 0.6 mg/kg than after rocuronium 0.9 mg/kg. Also, we hypothesised that time to TOF-2 would be shorter after rocuronium 0.3 mg/kg than after rocuronium 0.6 mg/kg.METHODS: This was a secondary analysis of 50 elderly patients > 80 years; 16 patients received rocuronium 0.6 mg/kg, another 16 patients received rocuronium 0.9 mg/kg; and, finally, 18 patients received rocuronium 0.3 mg/kg. Patients received total intravenous anaesthesia, and neuromuscular block was monitored with acceleromyography.RESULTS: Time to TOF-2 was shorter after rocuronium 0.6 mg/kg than after rocuronium 0.9 mg/kg: 37 min. versus 59 min. (difference: 22 min. (95% confidence intervals (CI): 10 to 33 min.), p = 0.0007). Time to TOF-2 after rocuronium 0.3 mg/kg was shorter than after rocuronium 0.6 mg/kg: 19 min. versus 37 min. (difference: 18 min. (95% CI: 11 to 25 min.), p = 0.00006). However, only 33% of the patients receiving 0.3 mg/kg obtained full effect i.e. TOF-0.CONCLUSION: Time to TOF-2 was shorter after rocuronium 0.6 mg/kg than after 0.9 mg/kg and shorter after rocuronium 0.3 mg/kg than after 0.6 mg/kg.FUNDING: This work was supported by departmental sources.TRIAL REGISTRATION: This study was a secondary analysis of two clinical trials.CLINICALTRIALS: gov (NCT04512313), (NCT03857750).
AB - INTRODUCTION: The effect of neuromuscular blocking agents may be reversed by administration of neostigmine, when two twitches are present using train-of-four (TOF) stimulation. However, in elderly patients, limited data are available about when to administer neostigmine. We hypothesised that time to two twitches after TOF (TOF-2) was shorter after rocuronium 0.6 mg/kg than after rocuronium 0.9 mg/kg. Also, we hypothesised that time to TOF-2 would be shorter after rocuronium 0.3 mg/kg than after rocuronium 0.6 mg/kg.METHODS: This was a secondary analysis of 50 elderly patients > 80 years; 16 patients received rocuronium 0.6 mg/kg, another 16 patients received rocuronium 0.9 mg/kg; and, finally, 18 patients received rocuronium 0.3 mg/kg. Patients received total intravenous anaesthesia, and neuromuscular block was monitored with acceleromyography.RESULTS: Time to TOF-2 was shorter after rocuronium 0.6 mg/kg than after rocuronium 0.9 mg/kg: 37 min. versus 59 min. (difference: 22 min. (95% confidence intervals (CI): 10 to 33 min.), p = 0.0007). Time to TOF-2 after rocuronium 0.3 mg/kg was shorter than after rocuronium 0.6 mg/kg: 19 min. versus 37 min. (difference: 18 min. (95% CI: 11 to 25 min.), p = 0.00006). However, only 33% of the patients receiving 0.3 mg/kg obtained full effect i.e. TOF-0.CONCLUSION: Time to TOF-2 was shorter after rocuronium 0.6 mg/kg than after 0.9 mg/kg and shorter after rocuronium 0.3 mg/kg than after 0.6 mg/kg.FUNDING: This work was supported by departmental sources.TRIAL REGISTRATION: This study was a secondary analysis of two clinical trials.CLINICALTRIALS: gov (NCT04512313), (NCT03857750).
KW - Humans
KW - Rocuronium/administration & dosage
KW - Neuromuscular Nondepolarizing Agents/administration & dosage
KW - Aged, 80 and over
KW - Female
KW - Male
KW - Neuromuscular Blockade/methods
KW - Neostigmine/administration & dosage
KW - Anesthesia Recovery Period
KW - Time Factors
KW - Neuromuscular Monitoring/methods
KW - Dose-Response Relationship, Drug
KW - Androstanols/administration & dosage
UR - http://www.scopus.com/inward/record.url?scp=85195438852&partnerID=8YFLogxK
U2 - 10.61409/A09230578
DO - 10.61409/A09230578
M3 - Journal article
C2 - 38847412
SN - 1603-9629
VL - 71
JO - Danish Medical Journal
JF - Danish Medical Journal
IS - 6
M1 - A09230578
ER -